BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 25503113)

  • 1. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review.
    Nishikawa H; Kita R; Kimura T; Osaki Y
    Anticancer Res; 2014 Dec; 34(12):6877-86. PubMed ID: 25503113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
    Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
    Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
    Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
    Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 9. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
    Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).
    Wiggermann P; Sieron D; Brosche C; Brauer T; Scheer F; Platzek I; Wawrzynek W; Stroszczynski C
    Med Sci Monit; 2011 Apr; 17(4):CR189-95. PubMed ID: 21455104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A; Hori S
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
    Idée JM; Guiu B
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
    Facciorusso A
    World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents.
    Brown DB; Pilgram TK; Darcy MD; Fundakowski CE; Lisker-Melman M; Chapman WC; Crippin JS
    J Vasc Interv Radiol; 2005 Dec; 16(12):1661-6. PubMed ID: 16371533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
    Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
    Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
    Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.